{"id":"https://openalex.org/W2156455388","doi":"https://doi.org/10.1592/phco.26.6.748","title":"Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study","display_name":"Atypical Antipsychotics and Pituitary Tumors: A Pharmacovigilance Study","alternate_titles":[],"publication_year":2006,"publication_date":"2006-06-01","ids":{"openalex":"https://openalex.org/W2156455388","doi":"https://doi.org/10.1592/phco.26.6.748","mag":"2156455388","pmid":"https://pubmed.ncbi.nlm.nih.gov/16716128"},"language":"en","primary_location":{"id":"doi:10.1592/phco.26.6.748","doi":"https://doi.org/10.1592/phco.26.6.748","is_oa":false,"landing_page_url":"https://doi.org/10.1592/phco.26.6.748","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2156455388"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5004527589","display_name":"Ana Szarfman","orcid":"https://orcid.org/0000-0001-6680-1423","observed_orcids":["https://orcid.org/0000-0001-6680-1423"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Ana Szarfman","raw_affiliation_strings":["Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA. szarfman@cder.fda.gov","Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland 20993-0002, USA. szarfman@cder.fda.gov","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]},{"raw_affiliation_string":"Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089253034","display_name":"Joseph M. Tonning","orcid":"https://orcid.org/0000-0003-2359-991X","observed_orcids":["https://orcid.org/0000-0003-2359-991X"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Joseph M. Tonning","raw_affiliation_strings":["Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013302942","display_name":"Jonathan G. Levine","orcid":"https://orcid.org/0000-0001-8078-2580","observed_orcids":["https://orcid.org/0000-0001-8078-2580"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jonathan G. Levine","raw_affiliation_strings":["Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Office of Pharmacoepidemiology and Statistical Sciences, Immediate Office, Center for Drug Evaluation and Research, United States Food and Drug Administration, Silver Spring, Maryland","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111699918","display_name":"Pudugramam Murali Doraiswamy","orcid":"https://orcid.org/0000-0003-0697-3893","observed_orcids":["https://orcid.org/0000-0003-0697-3893"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Murali Doraiswamy","raw_affiliation_strings":["Departments of Psychiatry and Medicine, Duke University Medical Center, Durham, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Departments of Psychiatry and Medicine, Duke University Medical Center, Durham, North Carolina","institution_ids":["https://openalex.org/I4210126298"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5004527589"],"corresponding_institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"],"apc_list":{"value":4030,"currency":"USD","value_usd":4030},"apc_paid":null,"fwci":11.7902,"has_fulltext":false,"cited_by_count":149,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.99505041,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"26","issue":"6","first_page":"748","last_page":"758"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9854000210762024,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.010200000368058681,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10832","display_name":"Pituitary Gland Disorders and Treatments","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.949999988079071},{"id":"https://openalex.org/keywords/pituitary-tumors","display_name":"pituitary tumors","score":0.9850000143051147},{"id":"https://openalex.org/keywords/hyperprolactinemia","display_name":"hyperprolactinemia","score":0.9760000109672546},{"id":"https://openalex.org/keywords/galactorrhea","display_name":"galactorrhea","score":1.0},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":0.9359999895095825},{"id":"https://openalex.org/keywords/dopamine-d2-receptor-antagonists","display_name":"dopamine D2 receptor antagonists","score":0.7990000247955322},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6190000176429749},{"id":"https://openalex.org/keywords/disproportionality-analysis","display_name":"disproportionality analysis","score":0.7929999828338623},{"id":"https://openalex.org/keywords/aripiprazole","display_name":"aripiprazole","score":0.765999972820282},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.9480000138282776},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/quetiapine","display_name":"quetiapine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/ziprasidone","display_name":"ziprasidone","score":0.9929999709129333},{"id":"https://openalex.org/keywords/haloperidol","display_name":"haloperidol","score":0.9990000128746033}],"concepts":[{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.7849158048629761},{"id":"https://openalex.org/C2780634440","wikidata":"https://www.wikidata.org/wiki/Q408535","display_name":"Quetiapine","level":3,"score":0.7583427429199219},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.7361471056938171},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.7314118146896362},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6811733841896057},{"id":"https://openalex.org/C2777270317","wikidata":"https://www.wikidata.org/wiki/Q205517","display_name":"Ziprasidone","level":4,"score":0.6054947376251221},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.6030988693237305},{"id":"https://openalex.org/C2777863693","wikidata":"https://www.wikidata.org/wiki/Q278515","display_name":"Galactorrhea","level":4,"score":0.5978949666023254},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5297535061836243},{"id":"https://openalex.org/C44208683","wikidata":"https://www.wikidata.org/wiki/Q15335165","display_name":"Dopamine receptor D2","level":3,"score":0.5103685259819031},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.507817804813385},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.48166072368621826},{"id":"https://openalex.org/C2780211496","wikidata":"https://www.wikidata.org/wiki/Q411188","display_name":"Aripiprazole","level":3,"score":0.47723984718322754},{"id":"https://openalex.org/C77088390","wikidata":"https://www.wikidata.org/wiki/Q8513","display_name":"Database","level":1,"score":0.4554573595523834},{"id":"https://openalex.org/C2778999636","wikidata":"https://www.wikidata.org/wiki/Q418785","display_name":"Amisulpride","level":4,"score":0.4375920593738556},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.41714394092559814},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3731813430786133},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3634698987007141},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.26808875799179077},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.23694637417793274},{"id":"https://openalex.org/C2779064019","wikidata":"https://www.wikidata.org/wiki/Q66590068","display_name":"Prolactin","level":3,"score":0.10400465130805969},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.09145882725715637},{"id":"https://openalex.org/C71315377","wikidata":"https://www.wikidata.org/wiki/Q11364","display_name":"Hormone","level":2,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0}],"mesh":[{"descriptor_ui":"D000068180","descriptor_name":"Aripiprazole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000069348","descriptor_name":"Quetiapine Fumarate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000568","descriptor_name":"Amenorrhea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003024","descriptor_name":"Clozapine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003987","descriptor_name":"Dibenzothiazepines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005687","descriptor_name":"Galactorrhea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006177","descriptor_name":"Gynecomastia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006220","descriptor_name":"Haloperidol","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006966","descriptor_name":"Hyperprolactinemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010911","descriptor_name":"Pituitary Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012737","descriptor_name":"Sex Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D016907","descriptor_name":"Adverse Drug Reaction Reporting Systems","qualifier_ui":"Q000706","qualifier_name":"statistics & numerical data","is_major_topic":true},{"descriptor_ui":"D018967","descriptor_name":"Risperidone","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1592/phco.26.6.748","doi":"https://doi.org/10.1592/phco.26.6.748","is_oa":false,"landing_page_url":"https://doi.org/10.1592/phco.26.6.748","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},{"id":"pmid:16716128","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16716128","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1526407019","https://openalex.org/W1562907257","https://openalex.org/W1969676529","https://openalex.org/W1972891674","https://openalex.org/W1981809734","https://openalex.org/W1985101172","https://openalex.org/W1990625891","https://openalex.org/W1997845538","https://openalex.org/W2015487160","https://openalex.org/W2032902988","https://openalex.org/W2033879609","https://openalex.org/W2037531474","https://openalex.org/W2039594635","https://openalex.org/W2048063537","https://openalex.org/W2048507943","https://openalex.org/W2051225255","https://openalex.org/W2053301065","https://openalex.org/W2062344473","https://openalex.org/W2074699312","https://openalex.org/W2083991698","https://openalex.org/W2101762862","https://openalex.org/W2106794142","https://openalex.org/W2108450329","https://openalex.org/W2111883919","https://openalex.org/W2135800205","https://openalex.org/W2142095149","https://openalex.org/W2153780972","https://openalex.org/W2159155203","https://openalex.org/W2162884145","https://openalex.org/W4213318649","https://openalex.org/W4237957049"],"related_works":["https://openalex.org/W2904195789","https://openalex.org/W7099951599","https://openalex.org/W2047965433","https://openalex.org/W1974853950","https://openalex.org/W4403257674","https://openalex.org/W2259441313","https://openalex.org/W4415404241","https://openalex.org/W3145608880","https://openalex.org/W100441917","https://openalex.org/W1997822118"],"abstract_inverted_index":{"STUDY":[0],"OBJECTIVE:":[1],"To":[2,68,104],"analyze":[3],"the":[4,65,112,123,154,161,163,166,177,206,212,219,266,270,278,312],"disproportionality":[5],"of":[6,8,45,61,78,107,137,165,211,269,280],"reporting":[7,59,76,156,180],"hyperprolactinemia,":[9],"galactorrhea,":[10],"and":[11,29,98,171,197,209,233,263,310,317],"pituitary":[12,46,79,198,274,300],"tumors":[13,47,63,223,275],"with":[14,49,85,226,289,299,306],"seven":[15,83,207,282],"widely":[16],"used":[17,111],"antipsychotic":[18],"drugs.":[19],"DESIGN:":[20],"Retrospective":[21],"pharmacovigilance":[22],"study.":[23],"DATA":[24],"SOURCE:":[25],"United":[26],"States":[27],"Food":[28],"Drug":[30],"Administration's":[31],"Adverse":[32],"Event":[33],"Reporting":[34],"System":[35],"(AERS)":[36],"database.":[37,67,125,221],"INTERVENTION:":[38],"We":[39],"initially":[40],"identified":[41],"higher-than-expected":[42],"postmarketing":[43],"reports":[44,81],"associated":[48,225,298],"risperidone,":[50,96,295],"a":[51,129,169],"potent":[52,290],"dopamine":[53],"D2-receptor":[54,291],"antagonist":[55],"antipsychotic,":[56],"by":[57],"analyzing":[58],"patterns":[60,77],"these":[62,108,244,256,281],"in":[64,147,218,249,261],"AERS":[66,124,220],"further":[69],"examine":[70],"this":[71],"association,":[72],"we":[73,110],"analyzed":[74],"disproportionate":[75],"tumor":[80,199],"for":[82,88,182,215,241,243,255,273,284,314],"antipsychotics":[84],"different":[86],"affinities":[87,279],"blocking":[89],"D2":[90,285],"receptors:":[91],"aripiprazole,":[92],"clozapine,":[93],"olanzapine,":[94],"quetiapine,":[95],"ziprasidone,":[97],"haloperidol.":[99],"MEASUREMENTS":[100],"AND":[101],"MAIN":[102],"RESULTS:":[103],"conduct":[105],"both":[106],"analyses,":[109],"Multi-item":[113],"Gamma":[114],"Poisson":[115],"Shrinker":[116],"(MGPS)":[117],"data":[118],"mining":[119],"algorithm":[120],"applied":[121],"to":[122,132,277],"The":[126,152,238],"MGPS":[127],"uses":[128],"Bayesian":[130],"model":[131],"calculate":[133],"adjusted":[134,155,179],"observed:expected":[135],"ratios":[136,181],"drug-adverse":[138],"event":[139],"associations":[140],"(Empiric":[141],"Bayes":[142],"Geometric":[143],"Mean":[144],"[EBGM]":[145],"values)":[146],"huge":[148],"drug":[149,170],"safety":[150],"databases.":[151],"higher":[153,248],"ratio,":[157],"or":[158],"EBGM":[159,239,253,271],"value,":[160],"greater":[162],"strength":[164],"association":[167],"between":[168],"an":[172],"adverse":[173,245],"event.":[174],"Risperidone":[175],"had":[176],"highest":[178,213],"hyperprolactinemia":[183],"(EBGM":[184,192,200],"34.9,":[185],"90%":[186,194,202],"confidence":[187],"interval":[188],"[CI]":[189],"32.8-37.1]),":[190],"galactorrhea":[191],"19.9,":[193],"CI":[195,203],"18.6-21.4),":[196],"18.7,":[201],"14.9-23.3)":[204],"among":[205],"antipsychotics,":[208],"one":[210],"scores":[214],"all":[216],"drugs":[217,283],"Some":[222],"were":[224,247,258],"visual":[227],"field":[228],"defects,":[229],"hemorrhage,":[230],"convulsions,":[231],"surgery,":[232],"severe":[234],"(>10-fold)":[235],"prolactin":[236],"elevations.":[237],"values":[240,254,272],"risperidone":[242],"events":[246,257],"women,":[250],"but":[251],"high":[252],"also":[259],"seen":[260],"men":[262],"children.":[264],"Moreover,":[265],"rank":[267],"order":[268],"corresponded":[276],"receptors.":[286],"CONCLUSION:":[287],"Treatment":[288],"antagonists,":[292],"such":[293],"as":[294],"may":[296],"be":[297],"tumors.":[301],"These":[302],"findings":[303],"are":[304],"consistent":[305],"animal":[307],"(mice)":[308],"studies":[309],"raise":[311],"need":[313],"clinical":[315],"awareness":[316],"longitudinal":[318],"studies.":[319]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2156455388","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":12},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":13},{"year":2012,"cited_by_count":10}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
